Innovation is now rooted in local realities

The 2026 ASCO Breakthrough meeting unites Asia-Pacific oncologists to advance cutting-edge research and collaboration. Dr Vanita Noronha, renowned oncologist at Tata Memorial Hospital (TMH), discusses innovations in cancer care and the importance of clinicians submitting research and participating in discussions at the event. Dr Noronha is also part of the ASCO Breakthrough Program Committee

- 

As a cancer survivor and oncologist at TMH, Mumbai, how has your work and personal experience shaped your cancer research and treatment approach in India?

As an oncologist and a breast cancer survivor in a low- and middle-income country (LMIC), my personal journey has deeply shaped how I approach cancer research and care.

At TMH, we care for thousands of patients annually, with many having severe financial constraints for even basic medical care. My experience in battling cancer has made me even more committed to driving innovations in oncology that are effective and accessible.

At TMH, our research mostly focuses on cost-effective, pragmatic solutions suited to patients and healthcare systems, like low-cost immunotherapy regimens. I strongly believe that patient-centred research grounded in clinical evidence and socioeconomic reality can maximise patient impact. My journey has reinforced that science must serve people, not just publications.

What key trends and shifts have you observed in India's cancer research towards molecular profiling, immunotherapy, and personalized medicine?

Indian oncology has evolved from a one-sized-fits-all approach to one based on personalised, precision- oriented, and pragmatic care. Innovation is now rooted in local realities.